Literature DB >> 22842566

Clustered DNA methylation changes in polycomb target genes in early-stage liver cancer.

Yao-Li Chen1, Chih-Jan Ko, Ping-Yi Lin, Wan-Ling Chuang, Chia-Chen Hsu, Pei-Yi Chu, Mei-Yu Pai, Chun-Chun Chang, Ming-Han Kuo, Yi-Ru Chu, Chun-Hsin Tung, Tim H-M Huang, Yu-Wei Leu, Shu-Huei Hsiao.   

Abstract

Polycomb-group proteins mark specific chromatin conformations in embryonic and somatic stem cells that are critical for maintenance of their "stemness". These proteins also mark altered chromatin modifications identified in various cancers. In normal differentiated cells or advanced cancerous cells, these polycomb-associated loci are frequently associated with increased DNA methylation. It has thus been hypothesized that changes in DNA methylation status within polycomb-associated loci may dictate cell fate and that abnormal methylation within these loci may be associated with tumor development. To assess this, we examined the methylation states of four polycomb target loci -Trip10, Casp8AP2, ENSA, and ZNF484 - in liver cancer. These four targets were selected because their methylation levels are increased during mesenchymal stem cell-to-liver differentiation. We found that these four loci were hypomethylated in most early-stage liver cancer specimens. For comparison, two non-polycomb tumor suppressor genes, HIC1 and RassF1A, were also examined. Whereas the methylation level of HIC1 did not differ significantly between normal and tumor samples, RassF1A was significantly hypermethylated in liver tumor samples. Unsupervised clustering analysis classified the methylation changes within polycomb and non-polycomb targets to be independent, indicating independent epigenetic evolution. Thus, pre-deposited polycomb marks within somatic stem cells may contribute to the determination of methylation changes during hepatic tumorigenesis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842566     DOI: 10.1016/j.bbrc.2012.07.084

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Epigenetic silencing of HIC1 promotes epithelial-mesenchymal transition and drives progression in esophageal squamous cell carcinoma.

Authors:  Pei Li; Xiang Liu; Zi-Ming Dong; Zhi-Qiang Ling
Journal:  Oncotarget       Date:  2015-11-10

2.  Hypermethylation of the HIC1 promoter and aberrant expression of HIC1/SIRT1 contribute to the development of thyroid papillary carcinoma.

Authors:  Wenyi Wu; Liting Zhang; Jianqing Lin; Hanwei Huang; Bai Shi; Xingong Lin; Zhongxin Huang; Chaoyang Wang; Jianlong Qiu; Xiaolong Wei
Journal:  Oncotarget       Date:  2016-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.